Prevention of β Thalassemia in Northern Israel - A cost-benefit analysis

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 6, Issue 1, 2014, Pages

  Koren, Ariel ^a,b   Profeta, Lora ^a,b   Zalman, Luci ^a   Palmor, Haya ^a   Levin, Carina ^a,b   Zamir, Ronit Bril ^a   Shalev, Stavit ^a,b   Blondheim, Orna ^a,b  

^a HAEMEK MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FERRIRPROX; FOLIC ACID; PEGINTERFERON; RIBAVIRIN; THYROXINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; BUDGET; CARDIOMYOPATHY; CHELATION THERAPY; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DIAGNOSTIC PROCEDURE; FEMALE; FETUS; FOLLOW UP; HEALTH CARE COST; HEPATITIS C; HOSPITAL FINANCE; HOSPITALIZATION; HUMAN; HYPOPARATHYROIDISM; HYPOTHYROIDISM; INSULIN DEPENDENT DIABETES MELLITUS; IRON CHELATION; ISRAEL; LIFE EXPECTANCY; MALE; NEWBORN; OSTEOPOROSIS; PEDIATRIC WARD; PRENATAL DIAGNOSIS; PREVALENCE; PROPHYLAXIS; SCREENING; THALASSEMIA MAJOR; BETA THALASSEMIA; COST OF ILLNESS; DETERIORATION; HEALTH PROGRAM; MASS SCREENING; PREVENTIVE MEDICINE;

EID: 84902325424     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2014.012     Document Type: Article

References (26)

1. Angastiniotis M, Modell B, Englezos P, Boulyjenkov V. Prevention and control of haemoglobinopathies. Bull World Health Organ. 1995;73(3):375-86.
2. Koren A, Zalman L, Palmor H, Ekstein E, Schneour Y, Schneour A, et al. [The prevention programs for beta thalassemia in the Jezreel and Eiron valleys: results of fifteen years experience]. Harefuah. 2002;141(11):938-43, 1210.
3. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood. 2011;118(13):3479-88. http://dx.doi.org/10.1182/blood-2010-08-300335
4. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353(11):1135-46. http://dx.doi.org/10.1056/NEJMra050436
5. Karnon J, Zeuner D, Brown J, Ades AE, Wonke B, Modell B. Lifetime treatment costs of beta-thalassaemia major. Clin Lab Haematol. 1999;21(6):377-85. http://dx.doi.org/10.1046/j.1365-2257.1999.00262.x
6. Pansatiankul B, Saisorn S. A community-based thalassemia prevention and control model in northern Thailand. J Med Assoc Thai. 2003;86 Suppl 3:S576-82.
7. Bozkurt G. Results from the north cyprus thalassemia prevention program. Hemoglobin. 2007;31(2):257-64. http://dx.doi.org/10.1080/03630260701297204
8. Memish ZA, Saeedi MY. Six-year outcome of the national premarital screening and genetic counseling program for sickle cell disease and beta-thalassemia in Saudi Arabia. Ann Saudi Med. 2011;31(3):229-35. http://dx.doi.org/10.4103/0256-4947.81527
9. Cao A, Rosatelli C, Galanello R, Monni G, Olla G, Cossu P, et al. The prevention of thalassemia in Sardinia. Clin Genet. 1989;36(5):277-85.
10. Ostrowsky JT, Lippman A, Scriver CR. Cost-benefit analysis of a thalassemia disease prevention program. Am J Public Health. 1985;75(7):732-6. http://dx.doi.org/10.2105/AJPH.75.7.732
11. Koren A, Zalman L, Palmor H, Zamir RB, Levin C, Openheim A, et al. Sickle cell anemia in northern Israel: screening and prevention. Isr Med Assoc J. 2009;11(4):229-34.
12. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-93.
13. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355(9220):2051-2. http://dx.doi.org/10.1016/S0140-6736(00)02357-6
14. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26-36. http://dx.doi.org/10.1159/000203853
15. Ginsberg G. TT, Filon D., Goldfarb A., Abramov A., Rachmilevitz E.A. Cost-benefit analysis of a national thalassaemia prevention programme in Israel. J Med Screen. 1998;5:120-6. http://dx.doi.org/10.1136/jms.5.3.120
16. Cronin EK, Normand C, Henthorn JS, Graham V, Davies SC. Organisation and cost-effectiveness of antenatal haemoglobinopathy screening and follow up in a community-based programme. BJOG. 2000;107(4):486-91. http://dx.doi.org/10.1111/j.1471-0528.2000.tb13267.x
17. Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47(10):1919-29. http://dx.doi.org/10.1111/j.1537-2995.2007.01416.x
18. Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics. 2007;25(4):329-42. http://dx.doi.org/10.2165/00019053-200725040-00005
19. Scriver CR, Bardanis M, Cartier L, Clow CL, Lancaster GA, Ostrowsky JT. Beta-thalassemia disease prevention: genetic medicine applied. Am J Hum Genet. 1984;36(5):1024-38.
20. Ho WL, Lin KH, Wang JD, Hwang JS, Chung CW, Lin DT, et al. Financial burden of national health insurance for treating patients with transfusion-dependent thalassemia in Taiwan. Bone Marrow Transplant. 2006;37(6):569-74. http://dx.doi.org/10.1038/sj.bmt.1705287
21. Modell B. Assesing Epidemiology and Health Burden of Haemoglobin Disorders. WHO; 1996.
22. Ghotbi N, Tsukatani T. Evaluation of the national health policy of thalassaemia screening in the Islamic Republic of Iran. East Mediterr Health J. 2005;11(3):308-18.
23. Najmabadi H, Ghamari A, Sahebjam F, Kariminejad R, Hadavi V, Khatibi T, et al. Fourteen-year experience of prenatal diagnosis of thalassemia in Iran. Community Genet. 2006;9(2):93-7. http://dx.doi.org/10.1159/000091486
24. Sruamsiri R, Chaiyakunapruk N, Pakakasama S, Sirireung S, Sripaiboonkij N, Bunworasate U, et al. Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program. BMC Health Serv Res. 2013;13:45. http://dx.doi.org/10.1186/1472-6963-13-45
25. Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic cell transplantation. Blood. 2012;120(8):1545-51. http://dx.doi.org/10.1182/blood-2012-05-426783
26. Majhail NS, Mau LW, Denzen EM, Arneson TJ. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database. Bone Marrow Transplant. 2013;48(2):294-300. http://dx.doi.org/10.1038/bmt.2012.133